Cancer discovery
Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D Inhibitor.
Ling Xie, Chunwei Xu, Han Si, Xiaoshuang Fu, Xiangcai Yang, Jianan Jin, Xiaoqing Yu, Zhiying Shao, Yanling Wang, Tianqing Chu, Jun Zhang, Rong Liang, Rui Meng, Yuchen Fei, Haolin Song
Published: 202610.1158/2159-8290.CD-25-1346
Abstract
KRAS G12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRAS G12D inhibitor that inhibits proliferation of KRAS G12D-mutant cells and demonstrates signif…
Preview only. Read the full abstract at the source